Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 1225037-39-7
2. Pqr309
3. Pi3k-in-2
4. Pqr-309
5. 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
6. Ncb5
7. Bimiralisib [inn]
8. Bimiralisib [usan]
9. Bimiralisib [who-dd]
10. Bimiralisib (pqr309)
11. 6z3qhb00lb
12. Nc-b5
13. Chembl4084907
14. 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
15. 2-pyridinamine, 5-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-
16. 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine
17. Mfcd28902193
18. Pqr309; Bimiralisib
19. Pqr-309(bimiralisib)
20. Bimiralisib (usan/inn)
21. Pqr-309(bimiralisib)?
22. Unii-6z3qhb00lb
23. Gtpl8383
24. Schembl1309049
25. Pqr309; Bimiralisib Free Base
26. Pqr 309
27. Bimiralisib [usan:inn:who-dd]
28. Bcp15887
29. Ex-a2018
30. Bdbm50240975
31. Nsc785117
32. S8738
33. Akos027439949
34. Cs-4672
35. Db14846
36. Nsc-785117
37. Ac-31532
38. As-49856
39. Hy-12868
40. D11440
41. N11425
42. Brd-k62374002-001-01-5
43. Q27088437
44. 5-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-2-pyridinamine
45. 5-[4,6-bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine
46. A3w
Molecular Weight | 411.4 g/mol |
---|---|
Molecular Formula | C17H20F3N7O2 |
XLogP3 | 1.3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 3 |
Exact Mass | Da |
Monoisotopic Mass | Da |
Topological Polar Surface Area | 103 |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 506 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
51
PharmaCompass offers a list of Bimiralisib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Bimiralisib manufacturer or Bimiralisib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Bimiralisib manufacturer or Bimiralisib supplier.
PharmaCompass also assists you with knowing the Bimiralisib API Price utilized in the formulation of products. Bimiralisib API Price is not always fixed or binding as the Bimiralisib Price is obtained through a variety of data sources. The Bimiralisib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Bimiralisib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bimiralisib, including repackagers and relabelers. The FDA regulates Bimiralisib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bimiralisib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Bimiralisib supplier is an individual or a company that provides Bimiralisib active pharmaceutical ingredient (API) or Bimiralisib finished formulations upon request. The Bimiralisib suppliers may include Bimiralisib API manufacturers, exporters, distributors and traders.
Bimiralisib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bimiralisib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bimiralisib GMP manufacturer or Bimiralisib GMP API supplier for your needs.
A Bimiralisib CoA (Certificate of Analysis) is a formal document that attests to Bimiralisib's compliance with Bimiralisib specifications and serves as a tool for batch-level quality control.
Bimiralisib CoA mostly includes findings from lab analyses of a specific batch. For each Bimiralisib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bimiralisib may be tested according to a variety of international standards, such as European Pharmacopoeia (Bimiralisib EP), Bimiralisib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bimiralisib USP).